Welcome to the e-CCO Library!

P499: A comparison of health-related quality of life in nurse-led vs. conventional inflammatory bowel disease follow-up
Year: 2018
Source: ECCO '18 Vienna
Authors:

L. Alvestad1*, L.-P. Jelsness-Jørgensen2,3, R. Goll4, A. Clancy5, P.C. Valle6, A.R. Broderstad7

Created: Thursday, 21 February 2019, 9:14 AM
P499: Accessing ultrasonographic transmural healing in patients with Crohn’s disease after induction therapy with infliximab: should we aim for higher infliximab trough levels?
Year: 2022
Source: ECCO'22
Authors: Morão, B.(1);Frias Gomes, C.(1);Revés, J.(1);Cúrdia Gonçalves, T.(2);Freitas, M.(2);Castro, F.(2);Moreira, M.J.(2);Cotter, J.(2);Pereira, F.(3);Caldeira, A.(3);Sousa, R.(3);Coelho, R.(4);Macedo, G.(4);Macedo, C.(5);Ferreira, M.(5);Glória, L.(1);Torres, J.(1);Palmela, C.(1);
Created: Friday, 11 February 2022, 3:56 PM
P499: Efficacy and safety of 2 or 3 vedolizumab intravenous infusions as induction therapy for ulcerative colitis and Crohn’s disease: results from VISIBLE 1 and 2
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

E. V. LoftusJr1, W. J. Sandborn2, D. Wolf3, S. Danese4, J. Chen5, X. Yao5, K. Kisfalvi*5, S. Vermeire6

Created: Friday, 22 February 2019, 9:41 AM
P499: Exclusive enteral nutrition induces transmural healing in adults with active Crohn's disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Chu, M.(1)*;Day, A.(1);Mathias, R.(1);Direen, T.(2);Broad, L.(3);Lynch, K.(4);Bryant, R.(1);
Created: Friday, 14 July 2023, 11:05 AM
P499: Long-term outcomes of infliximab and predictors of response in 213 patients with ulcerative colitis: a hospital-based cohort study from Korea
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

H. Seo*1, S. H. Park1, K. Chang1, G.-U. Kim1, E. M. Song1, M. Seo1, H.-S. Lee2, S.W. Hwang1, D.-H. Yang1, B. D. Ye1, J.-S. Byeon1, S.-J. Myung1, S.-K. Yang1

Created: Friday, 22 February 2019, 9:49 AM
P499: Sexual dysfunction is frequent among inflammatory bowel disease patients: results of a prospective study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Rivière P.*1, Zallot C.2, Desobry P.3, Sabaté J.-M.4, Vergniol J.1, Zerbib F.1, Peyrin-Biroulet L.2, Laharie D.1, Poullenot F.1

Created: Wednesday, 20 February 2019, 10:36 AM
P499: Use of an Inflammatory Bowel Disease illustrated guide as a patient education tool
Year: 2021
Source: ECCO'21 Virtual
Authors: Murray, J.(1);Lindsay, J.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P500 Adiposity among IBD patients
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Bletsa1, A. Karachaliou2, G. Kokkotis3, M.M. Tsoutska1, S. Andoniadi2, I. Papaconstantinou4, M. Kontogianni2, G. Bamias3

Created: Thursday, 30 January 2020, 10:12 AM
P500: Assessing physical activity, fatigue and quality of life in an outpatient cohort of IBD patients
Year: 2021
Source: ECCO'21 Virtual
Authors: Janssen , L.M.(1,2);Hendrix, E.M.B.(1,2);Spooren , C.E.G.M.(1,2);Stassen , L.P.S.(2,3);Pierik , M.J.(1,2);Jonkers , D.M.A.E.(1,2);
Created: Wednesday, 2 June 2021, 4:12 PM
P500: Capsule endoscopy reveals small intestinal mucosal Crohn’s disease healing after treatment with adalimumab: preliminary results of the SIMCHA study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

E. Seidman*1, U. Kopylov2, C.-Y. Chao1, M. Girardin3, M. Starr4

Created: Friday, 22 February 2019, 9:49 AM
P500: Effectiveness and safety in Crohn's disease patients who were treated with CT-P13
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Choe Y.H.*1, Lee S.-H.2, Park D.I.3, Lee J.H.4, Kim H.J.5, Kim Y.-H.6, Choi C.H.7, Eun C.S.8, Lee S.J.9, Lee S.9

Created: Wednesday, 20 February 2019, 10:36 AM
P500: Post-marketing safety experience of vedolizumab in patients receiving concomitant treatment with other biologics
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. D. Cohen1, F. Bhayat2, A. Blake2, S. Travis*3

Created: Friday, 22 February 2019, 9:41 AM
P500: Real life 2 year experience with ustekinumab in a Spanish open-label cohort of ulcerative colitis patients.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Iborra Colomino, M.I.(1)*;Ferreiro-Iglesias, R.(2);Martín-Arranz, M.D.(3);Mesonero-Gismero, F.(4);Mínguez, A.(1);Porto Silva, S.(2);García-Ramírez, L.(5);García de la Filia, I.(4);Bastida, G.(1);Nieto García, L.(2);Suárez Ferrer, C.(3);Aguas, M.(1);Barreiro de Acosta, M.(2);Nos, P.(1);
Created: Friday, 14 July 2023, 11:05 AM
P500: The effects of EBV naïve status on treatment decisions in patients with inflammatory bowel disease: Does the risk of GI lymphoma justify the cost?
Year: 2018
Source: ECCO '18 Vienna
Authors:

T. Ahmed1, F. Brown1, R. Ahmed1, S. Whitehead2, H. Steed1, M.J. Brookes1*

Created: Thursday, 21 February 2019, 9:14 AM
P500: The use of budesonide results in lower risk for infections compared to systemic glucocorticoids
Year: 2022
Source: ECCO'22
Authors: Pallmer, K.(1);Timeus, S.(2);Laoun, R.(1);
Created: Friday, 11 February 2022, 3:56 PM
P501 Thiopurine withdrawal in patients with Crohn’s disease: the SURESTE study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

E. Sánchez Rodríguez1, R. Sánchez Aldehuelo1, J. Guardiola2, A. Gutiérrez Casbas3, E. Domènech4, F. Bermejo5, M. Van-Domselaar6, F. Mesonero Gismero1, G. Suris2, R. Muñoz Perez3, M. Mañosa4, L. Jiménez Márquez5, A. Algaba García5, A. López sanroman1, SURESTE

Created: Thursday, 30 January 2020, 10:12 AM
P501: Abdominal obesity in Paediatric Crohn’s disease is associated with adipokine dysregulation
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

D. Thangarajah*1, K. E. Chapell1, S. Mandalia1, G. Frost2, J. M. Fell3

Created: Friday, 22 February 2019, 9:49 AM
P501: Baseline characteristics of Crohn's disease patients in the vedolizumab PASS study: a cohort study assessing the safety and effectiveness of vedolizumab compared to other biologic agents (02)
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Siegel C.A.*1, Lichtenstein G.2, Siegmund B.3, Lewis J.D.2, Wolf D.4, Louis E.5, Sebastian S.6, Hebuterne X.7, Bell A.8, Söderman C.9, Schubert S.10, Atreya R.11, Polyak S.12, Hoque S.13, Krummenerl A.14, Bokemeyer B.15, Krummenerl T.16, Shulmann S.17, Karlén P.18, Moum B.19, Dolin P.20

Created: Wednesday, 20 February 2019, 10:36 AM
P501: High TNF-production of CD14+ cells and short disease duration are independent predictive factors for response to Infliximab treatment
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

D. Lissner*1, B. Jessen1,2, E. Sonnenberg1, M. Schumann1, F. Schmidt1, Y. Rodriguez Sillke1, B. Siegmund1

Created: Friday, 22 February 2019, 9:41 AM
P501: Incidence and therapeutic management/treatment of very early onset inflammatory bowel disease during 2015-2020.
Year: 2021
Source: ECCO'21 Virtual
Authors: Ninh, G.(1);Wewer, V.(1);Jakobsen, C.(1);
Created: Wednesday, 2 June 2021, 4:12 PM